ENTRY       D10025                      Drug
NAME        Semaglutide (USAN/INN);
            Semaglutide (genetical recombination) (JAN);
            Ozempic (TN)
PRODUCT     ORAL SEMAGLUTIDE (Novo Nordisk Pharmaceutical Industries)
            OZEMPIC (A-S Medication Solutions)
            OZEMPIC (A-S Medication Solutions)
            OZEMPIC (A-S Medication Solutions)
            OZEMPIC (Novo Nordisk Pharmaceutical Industries)
            WEGOVY (A-S Medication Solutions)
            WEGOVY (Novo Nordisk Pharmaceutical Industries)
FORMULA     C187H291N45O59
EXACT_MASS  4111.1154
MOL_WEIGHT  4113.58
SEQUENCE    HXEGTFTSDV SSYLEGQAAK EFIAWLVRGR G
  TYPE      Peptide
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG01493  GLP-1 receptor agonist
REMARK      Therapeutic category: 2499
            ATC code: A10BJ06
            Product: D10025<JP/US>
            Product (mixture): D13245<JP>
EFFICACY    Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
  TYPE      Modified peptide
TARGET      GLP1R [HSA:2740] [KO:K04581]
  PATHWAY   hsa04080(2740)  Neuroactive ligand-receptor interaction
            hsa04911(2740)  Insulin secretion
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BJ Glucagon-like peptide-1 (GLP-1) analogues
                 A10BJ06 Semaglutide
                  D10025  Semaglutide (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Anti-Obesity Agents
              Semaglutide
               D10025  Semaglutide (USAN/INN)
             Blood Glucose Regulators
              Antidiabetic Agents
               GLP-1 Receptor Agonist
                Semaglutide
                 D10025  Semaglutide (USAN/INN)
             Kidney Agents
              GLP-1 Receptor Agonist
               Semaglutide
                D10025  Semaglutide (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              24  Hormones
               249  Miscellaneous
                2499  Others
                 D10025  Semaglutide (USAN/INN); Semaglutide (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01493  GLP-1 receptor agonist
                D10025  Semaglutide
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Secretin receptor family
               Glucagon
                GLP1R
                 D10025  Semaglutide (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10025
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10025
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10025
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10025
DBLINKS     CAS: 910463-68-2
            PubChem: 172232422
            ChEBI: 167574
///